Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill shows promise in shrinking spleens for myelofibrosis patients

NCT ID NCT05020652

First seen Jan 04, 2026 · Last updated Jun 18, 2026 · Updated 30 times

Summary

This study tested a new drug called TQ05105 in 107 people with moderate to high-risk myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen. The goal was to see if TQ05105 could shrink the spleen better than the standard drug hydroxyurea. Participants took either TQ05105 or hydroxyurea for 24 weeks, and doctors measured spleen size using scans. The trial is complete, and results will show if TQ05105 is a more effective treatment option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, 510055, China

  • Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, 300020, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100005, China

  • West China School of Medicine / West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

Conditions

The condition(s) this trial relates to.

follicular lymphoma myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.